Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Octocog alfa, plasma/albumin-free method.

Paul L McCormack1, Greg L Plosker

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 6, 2006
PubMed
Summary

Octocog alfa-PFM, a recombinant factor VIII, effectively treats bleeding in hemophilia A patients. This plasma/albumin-free method shows excellent efficacy and safety, with a very low risk of inhibitor development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.

Drugs·2016
Same author

Erratum to: Cariprazine: First Global Approval.

Drugs·2016
Same author

Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.

Drugs·2015
Same author

Evogliptin: First Global Approval.

Drugs·2015

Area of Science:

  • Hematology
  • Biotechnology
  • Pharmacology

Background:

  • Hemophilia A is a genetic bleeding disorder requiring factor VIII replacement therapy.
  • Traditional factor VIII products may carry risks associated with plasma-derived components.
  • Octocog alfa-PFM offers a recombinant, plasma/albumin-free alternative for factor VIII treatment.

Purpose of the Study:

  • To evaluate the hemostatic efficacy and safety of octocog alfa-PFM in patients with hemophilia A.
  • To assess the effectiveness of octocog alfa-PFM in various bleeding scenarios and patient populations.
  • To determine the incidence of adverse events and inhibitor development with octocog alfa-PFM.

Main Methods:

  • Clinical trials involving adolescents and adults with hemophilia A receiving prophylaxis.
  • Assessment of hemostatic efficacy in acute breakthrough bleeding episodes.
  • Evaluation of perioperative use and treatment in previously treated children.

Main Results:

  • Octocog alfa-PFM demonstrated excellent or good hemostatic efficacy in most acute bleeding episodes.
  • Efficacy was consistent across different bleeding causes, sites, and age groups, including children under 6.
  • The treatment was well-tolerated, with very few adverse events and a low risk of inhibitor development.

Conclusions:

  • Octocog alfa-PFM is an effective and safe treatment option for hemophilia A.
  • The plasma/albumin-free formulation minimizes risks associated with blood-borne pathogens.
  • Octocog alfa-PFM provides reliable hemostasis for acute bleeding and perioperative management in hemophilia A patients.

Related Experiment Videos